18F-labeled PSMA-targeted PET imaging agents

Patent metadata

Field	Value
Publication number	US-11554183-B2
Application number	US-201414774371-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	Jan 17, 2023
Grant date	Jan 17, 2023

Abstract

Compounds of Marlush formula (I) described in the claims are useful in diagnostic methods for detecting and/or identifying cells presenting PSMA. Disclosed are also methods for preparing the compounds. Representative compounds according to the application are:

First claim

We claim:

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof, wherein
each R is independently hydrogen or a protecting group.

2. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

3. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, excipient, and/or diluent.

4. A compound which is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein R is benzyl or tert-butyl.

6. A salt of a compound of claim 4 , wherein the salt is:

7. A salt of a compound of claim 4 , wherein the salt is:

8. A pharmaceutical composition comprising a salt of a compound of claim 4 , together with a pharmaceutically acceptable carrier, excipient, and/or diluent, wherein the salt is:

9. A pharmaceutical composition comprising a salt of a compound of claim 4 , together with a pharmaceutically acceptable carrier, excipient, and/or diluent wherein the salt is:

10. A pharmaceutical composition according to claim 8 , wherein the pharmaceutically acceptable carrier, excipient, and/or diluent comprises sterile saline.

11. A pharmaceutical composition according to claim 9 , wherein the pharmaceutically acceptable carrier, excipient, and/or diluent comprises sterile saline.

12. A compound which is

or a pharmaceutically acceptable salt thereof.

13. A salt of a compound of claim 12 , wherein the salt is:

14. A salt of a compound of claim 12 wherein the salt is:

15. A pharmaceutical composition comprising a salt of a compound of claim 12 , together with a pharmaceutically acceptable carrier, excipient, and/or diluent, wherein the salt is:

16. A pharmaceutical composition comprising a salt of a compound of claim 12 , together with a pharmaceutically acceptable carrier, excipient, and/or diluent wherein the salt is:

17. A pharmaceutical composition according to claim 15 , wherein the pharmaceutically acceptable carrier, excipient, and/or diluent comprises sterile saline.

18. A pharmaceutical composition according to claim 16 , wherein the pharmaceutically acceptable carrier, excipient, and/or diluent comprises sterile saline.

Assignees

• Cancer Targeted Tech Llc
• Univ Washington State

Inventors

• Berkman Clifford
• Stekhova Svetlana A

Classifications

• A61K51/0489 Primary

  Phosphates or phosphonates, e.g. bone-seeking phosphonates; (phospholipids: A61K51/0408; nucleotides or nucleic acids: A61K51/0491) · CPC title

• C07F9/58

  Pyridine rings · CPC title

• C07F9/2458

  of aliphatic amines · CPC title

• C07F9/2416

  of cycloaliphatic alcohols · CPC title

• A61K51/0402

  carboxylic acid carriers, fatty acids (amino acids A61K51/0406) · CPC title